semaglutide
How Semaglutide Exclusion Threw Pharmacies Off Course
The FDA's new 503B rule removes semaglutide from bulk drug lists, meaning pharmacies can no longer compound it in large volumes. This change forces hospitals and community outlets to redesign formularies, seek commercial sources, and confront higher costs for patients who rely on GLP-1 therapy. Medical Disclaimer: This